Orchestra Biomed Holdings, Inc. (OBIO) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026
Orchestra Biomed Holdings, Inc. (OBIO)
A forensic read on Orchestra Biomed Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-2.7
Distress distance
Clean
Earnings quality
5
Forensic signals
-3.0
P / E (ttm)
-98.4%
ROE
$263M
Market cap
0.00%
Dividend yield
1169.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Orchestra Biomed Holdings, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -2.7, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
464d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 285 to 464 FY2024→FY2025 (against cost of goods sold; inventory +79% vs -7% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-64.5%
FY2025
Return on invested capital.Return on invested capital is -64.5% in the latest fiscal year and slipping from -45% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
36% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 36% of revenue in FY2025 — about $0.25 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 4.6% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.
+51.9%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +51.9% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply, and much of it is accounted for. The build is led by inventory up +79% against -7% in cost of sales and PP&E up +24% against revenue +1169%. That build tracks a +1169% revenue year: net operating assets grew +70% and receivables +3%, so the balance sheet is carrying more volume rather than getting heavier per dollar of sales — the accrual build is funding demand the company is shipping, not earnings running ahead of collection. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 11% of net operating assets, diverging from the balance-sheet accrual read.
Key fundamentals
Latest Revenue$33.5M
Revenue Growth YoY+1169.2%
Revenue CAGR (3yr)+111.6%
Net Margin-157.4%
Free Cash Flow-$49.5M
Return on Equity-98.4%
Debt / Equity0.28x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Orchestra Biomed Holdings, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 12, 2026. Forensic signals flag probability, not certainty.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed +219% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +47.1%/yr figure isn't a real buyback/dilution read here.